Article Contents ::
Details About Generic Salt :: Rasagiline
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| 1F. DRUGS FOR NEURODEGENERATIVE DISORDERS in 1. NERVOUS SYSTEM |
| RASAGILINE |
| MAO TYPE B INHIBITOR | ANTI-PARKINSONIAN |
| PK: A: Rapid M: Hepatic E: Urine, feces |
|
Indications & Dose: PARKINSON’S DISEASE Mono therapy PO Adult 1mg OD | Combination therapy/Adjunct therapy PO Adult Initially 0.5mg/day, may increase to 1mg/day (based on response and tolerability) with levodopa |
| Contra: concomitant use of cyclobenzaprine/dextromethorphan/methadone/propoxyphene/tramadol/st.john’s wort, concomitant use of MAOIs/meperidine within 14 days of rasagiline, moderate to severe hepatic impairment
Precautions: mild hepatic impairment ADR: Serious: leucopenia, arthralgia, arthritis, depression, conjunctivitis, cerebrovascular accidents, MI, orthostatic hypotension, angina pectoris, Others: dyspepsia, anorexia, hallucinations, skin rashes, melanoma, urinary urgency, vertigo, rhinitis, Headache, flu-like syndrome, malaise, neck pain DDI: Serious Entacapone increases rasagiline clearance by 28%, Ciprofloxacin increases rasagiline levels, Trazodone lead to adverse effects (serotonin syndrome) Others MAOIs causes hypertensive reactions, SSRIs causes serotonin syndrome and other serious CNS disturbances Diet: Without food Monitor: BP, symptoms of parkinsonism, general mood & behavior, skin examination for presence of melanoma |
